ABL Texcell Diagnostics (9BK0) Stock Overview
Provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
9BK0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ABL Texcell Diagnostics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.20 |
| 52 Week High | €4.32 |
| 52 Week Low | €1.88 |
| Beta | -0.57 |
| 1 Month Change | 8.91% |
| 3 Month Change | -7.56% |
| 1 Year Change | -47.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9BK0 | DE Trade Distributors | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -1.1% | -1.1% |
| 1Y | -47.1% | 16.2% | 3.4% |
Return vs Industry: 9BK0 underperformed the German Trade Distributors industry which returned 16.2% over the past year.
Return vs Market: 9BK0 underperformed the German Market which returned 3.3% over the past year.
Price Volatility
| 9BK0 volatility | |
|---|---|
| 9BK0 Average Weekly Movement | 16.4% |
| Trade Distributors Industry Average Movement | 4.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9BK0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9BK0's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | Chalom Sayada | www.abldiagnostics.com |
ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK virus (BKV), human papillomavirus (HPV), respiratory syncytial virus (RSV), and salmonella; real time PCR assays; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, next generation sequencing (NGS) library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB.
ABL Texcell Diagnostics SA Fundamentals Summary
| 9BK0 fundamental statistics | |
|---|---|
| Market cap | €39.21m |
| Earnings (TTM) | €1.98m |
| Revenue (TTM) | €10.53m |
Is 9BK0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9BK0 income statement (TTM) | |
|---|---|
| Revenue | €10.53m |
| Cost of Revenue | €5.56m |
| Gross Profit | €4.97m |
| Other Expenses | €2.99m |
| Earnings | €1.98m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 47.17% |
| Net Profit Margin | 18.78% |
| Debt/Equity Ratio | 29.5% |
How did 9BK0 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 05:22 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABL Texcell Diagnostics SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jean-Pierre Loza | In Extenso Financement & Marché |